Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Pyxis Oncology, Inc. (PYXS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 21 K | 11.67 M | 48.02 M | 173.73 M | 124.6 M |
| 2022 | 598 K | -160,372,000 | 50.56 M | 211.38 M | 186.61 M |
| 2021 | -274,570,000 | 18.71 M | 280.02 M | 278.67 M | |
| 2020 | -7,300,000 | 25.8 M | 10.15 M | 8.1 M | |
| 2019 | -19,675,000 | 22.68 M | 19.81 M | 19.7 M |